UPDATE 2-Teva says aims to launch EpiPen-like device by 2018 in U.S.

Sept 9 (Reuters) - Teva Pharmaceutical Industries Ltd

said Friday it aims to win U.S. approval by late 2017

or early 2018 for its version of Mylan NV's EpiPen

device for treating severe allergic reactions, a move that would

challenge the branded product's overwhelming market dominance.

Read more